A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2520-1026
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial) ; volume:2 ; number:1 ; day:27 ; month:2 ; year:2018 ; pages:1-9 ; date:12.2018
BMC Rheumatology ; 2, Heft 1 (27.2.2018), 1-9, 12.2018
- Schlagwort
-
Augenheilkunde
Augenkrankheit
- Beteiligte Personen und Organisationen
-
Ramanan, Athimalaipet V.
Dick, Andrew D.
Jones, Ashley P.
Guly, Catherine
Hardwick, Ben
Hickey, Helen
Lee, Richard
McKay, Andrew
Beresford, Michael W.
SpringerLink (Online service)
- DOI
-
10.1186/s41927-018-0010-2
- URN
-
urn:nbn:de:1111-2018040819464
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ramanan, Athimalaipet V.
- Dick, Andrew D.
- Jones, Ashley P.
- Guly, Catherine
- Hardwick, Ben
- Hickey, Helen
- Lee, Richard
- McKay, Andrew
- Beresford, Michael W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
Adalimumab kann Uveitis im Rahmen einer JIA kontrollieren
Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis
Management of Uveitis Patients on Anti-TNF Agents Who Develop Demyelinating Disease – A Case Series
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Jia : = Jia
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Keine signifikante Verbesserung der juvenilen idiopathisch Arthritis-assoziierten Uveitis bei subkutaner Gabe von Tocilizumab
Protocol for the Foot in Juvenile Idiopathic Arthritis trial (FiJIA): a randomised controlled trial of an integrated foot care programme for foot problems in JIA
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
Adalimumab kann Uveitis im Rahmen einer JIA kontrollieren
Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis
Management of Uveitis Patients on Anti-TNF Agents Who Develop Demyelinating Disease – A Case Series
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Jia : = Jia
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Keine signifikante Verbesserung der juvenilen idiopathisch Arthritis-assoziierten Uveitis bei subkutaner Gabe von Tocilizumab
Protocol for the Foot in Juvenile Idiopathic Arthritis trial (FiJIA): a randomised controlled trial of an integrated foot care programme for foot problems in JIA
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
Adalimumab kann Uveitis im Rahmen einer JIA kontrollieren
Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis
Management of Uveitis Patients on Anti-TNF Agents Who Develop Demyelinating Disease – A Case Series
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Jia : = Jia
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Keine signifikante Verbesserung der juvenilen idiopathisch Arthritis-assoziierten Uveitis bei subkutaner Gabe von Tocilizumab
Protocol for the Foot in Juvenile Idiopathic Arthritis trial (FiJIA): a randomised controlled trial of an integrated foot care programme for foot problems in JIA
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis